Abreva is an over-the-counter cream used to treat cold sores (also called fever blisters) on the face or lips. Its active ingredient, docosanol 10%, is the only nonprescription cold sore medicine approved by the FDA that can actually shorten healing time. It’s approved for adults and children 12 and older.
How Abreva Treats Cold Sores
Cold sores are caused by the herpes simplex virus (HSV), which spreads by infecting healthy skin cells near the outbreak. Abreva works differently from most antiviral treatments. Rather than attacking the virus directly, it changes the surface of your skin cells so the virus can’t fuse with them and get inside. The active ingredient gets absorbed into cell membranes and essentially locks the door, preventing the virus from entering and replicating.
This is an important distinction. If you mix the virus with docosanol in a lab dish, the virus stays perfectly infectious. The drug only works once it’s been absorbed into your skin cells, where it alters the cell membrane in a way that blocks viral entry. That’s why applying it early matters so much.
Why Timing Makes a Big Difference
Abreva works best when you apply it at the very first sign of a cold sore, during what’s called the prodrome stage. That’s the initial tingling, burning, or redness you feel before a blister actually forms. At this point, the virus is just beginning to spread into neighboring cells, and blocking that process can limit how large and painful the sore becomes.
In clinical trials submitted to the FDA, people who applied Abreva during this early stage healed in a median of 4.0 days, compared to 4.7 days with a placebo. That’s roughly 18 hours faster. However, when treatment started later (after blisters had already formed), healing times were nearly identical between Abreva and placebo: 5.7 days versus 5.8 days. The takeaway is clear. If you wait until a full blister develops, Abreva loses most of its advantage.
How to Apply It
The recommended routine is five applications per day, rubbed gently into the affected area until the sore heals. Most cold sores resolve within a week or so. If yours hasn’t healed within 10 days, stop using the cream and check with a doctor, as that timeline could signal a secondary infection or a different condition.
Abreva is only meant for cold sores on the outside of your face and lips. It should not be applied inside your mouth, inside your nose, or near your eyes. It also won’t help with canker sores, which are a completely different condition that occurs inside the mouth and isn’t caused by a virus.
What Abreva Won’t Do
Abreva treats individual cold sore outbreaks. It does not cure herpes simplex, prevent future outbreaks, or reduce how contagious you are during an active sore. The virus remains dormant in nerve cells between outbreaks, and no topical cream can reach it there.
It’s also worth setting realistic expectations about the results. Even in the best-case scenario (early application at the first tingle), the difference is less than a day of faster healing. That’s meaningful when you’re dealing with a painful, visible sore on your lip, but Abreva isn’t going to make a cold sore disappear overnight. It shortens the episode modestly and may reduce the severity of blistering if caught early enough.
Brand Name vs. Generic
Generic versions of docosanol 10% cream are available and contain the same active ingredient at the same concentration. When a Canadian drug review board evaluated Abreva, it classified the product as offering “moderate, little or no therapeutic advantage” over existing cold sore treatments. The panel also noted that no single cold sore medication stood out as clearly superior to the others. In practical terms, generic docosanol should perform identically to brand-name Abreva, often at a lower price.
Side Effects
Docosanol is generally well tolerated. The most commonly reported side effects are mild and localized: slight skin irritation, dryness, or redness at the application site. Allergic reactions are rare. Because the drug works by modifying your own cell membranes rather than circulating through your bloodstream, systemic side effects are essentially nonexistent.
For children under 12, there isn’t enough data to confirm safety, so a doctor should weigh in before use in younger kids.